Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174056 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT01174056 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 39 participants.
The verdict
NCT01174056, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this research study is to gain understanding of the basic responses of the lung to inflammation and specifically if a certain medication can reduce the inflammation alone or in combination with another. Inflammation is the way our bodies react to irritation or injury, and involves red, warm, and often painful swelling of the affected tissue. "Acute lung injury" involves inflammation that is not specific to one area of the lung and is caused by any one of several conditions: infection, trauma, breathing toxic substances, etc. When lung injury is severe, not enough oxygen can get into the body; this can lead to the need for mechanical support of breathing (mechanical ventilation), problems with brain, heart or other organ function, and in some cases, death.
Interventions
- DRUG Pioglitazone
- DRUG Zileuton
- DRUG Pioglitazone placebo
- DRUG Zileuton placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174056
The ClinicalTrials.gov registry entry for NCT01174056 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pioglitazone is the first listed.
NCT01174056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174056 about?
NCT01174056 is a clinical study titled "Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging". The purpose of this research study is to gain understanding of the basic responses of the lung to inflammation and specifically if a certain medication can reduce the inflammation alone or in combination with another. Inflammation is the way our bodies react to irritation or injury, and involves red...
What is the current status of trial NCT01174056?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2011-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01174056?
The interventions under investigation include: Pioglitazone (DRUG), Zileuton (DRUG), Pioglitazone placebo (DRUG), Zileuton placebo (DRUG).
Who is sponsoring clinical trial NCT01174056?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.